发明名称 |
Modified parvovirus having enhanced anti-tumor efficacy |
摘要 |
Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substitution at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. |
申请公布号 |
US8916176(B2) |
申请公布日期 |
2014.12.23 |
申请号 |
US201213713889 |
申请日期 |
2012.12.13 |
申请人 |
Deutsches Krebsforschungszentrum |
发明人 |
Salome Nathalie;Dinsart Christiane;Michel Nadine;Rommelaere Jean |
分类号 |
A61K39/12;A61K39/23;A61K39/235;C12N7/00;A61K35/76;C12N15/86;C07K14/005;C07K16/08 |
主分类号 |
A61K39/12 |
代理机构 |
Perkins Coie LLP |
代理人 |
Perkins Coie LLP ;Kung Viola T. |
主权项 |
1. A method for treating cancer, comprising the step of administering to a patient a parvovirus variant derived from parvovirus H-1 (H-1PV) or a related rodent parvovirus, wherein said variant (a) has an amino acid substitution at position Lys96 and/or position Leu103 of NS-2 in SEQ ID NO: 13, or (b) has an in-frame deletion consisting of from nucleotides 2022 to 2135 in SEQ ID NO: 11, resulting in the translation of an NS1 protein having a deletion of amino acids 587-624 in SEQ ID NO: 12 and an NS2 protein having a deletion of amino acids 96-133 in SEQ ID NO: 13. |
地址 |
Heidelberg DE |